Chemotherapy-induced nausea and vomiting

被引：0
作者：
Karthaus, Meinolf [1 ]
机构：
[1] Klinikum Neuperlach, Med Klin 4, Hamatol Onkol Palliativmed, Oskar Maria Graf Ring 51, D-81737 Munich, Germany
来源：
HNO | 2023年 / 71卷 / 07期
关键词：
Combined modality therapy; Drug toxicity; Appetite; Anticipatory vomiting; Pre-exposure prophylaxis; HIGHLY EMETOGENIC CHEMOTHERAPY; FIXED-DOSE COMBINATION; DOUBLE-BLIND; PHASE-III; PREVENTION; EFFICACY; CANCER; SAFETY; PALONOSETRON; NETUPITANT;
D O I：
10.1007/s00106-023-01315-9
中图分类号：
R76 [耳鼻咽喉科学];
学科分类号：
100213 ;
摘要：
Chemotherapy-induced nausea and the subsequent vomiting (CINV) are adverse effects of cancer treatment associated with considerable burden for the patient. CINV has a significant negative impact on quality of life. The consequent loss of fluids and electrolytes can lead to impaired renal function or weight loss, which may lead to hospitalization. If CINV later results in anticipatory vomiting, this complicates both CINV prophylaxis and further chemotherapy, which can endanger the continuation of cancer treatment. The introduction of high-dose dexamethasone as well as 5-HT3 and NK1 receptor antagonists has led to a significant improvement of CINV prophylaxis since the 1990s. Recommendations on CINV prophylaxis are in available in guidelines. Adherence to these guidelines results in better outcomes.
引用
收藏
页码：473 / 484
页数：12
相关论文
共 36 条
[1]   A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy [J].
Aapro, M. ;
Rugo, H. ;
Rossi, G. ;
Rizzi, G. ;
Borroni, M. E. ;
Bondarenko, I. ;
Sarosiek, T. ;
Oprean, C. ;
Cardona-Huerta, S. ;
Lorusso, V. ;
Karthaus, M. ;
Schwartzberg, L. ;
Grunberg, S. .
ANNALS OF ONCOLOGY, 2014, 25 (07) :1328-1333
[2]   The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER) [J].
Aapro, M. ;
Molassiotis, A. ;
Dicato, M. ;
Pelaez, I. ;
Rodriguez-Lescure, A. ;
Pastorelli, D. ;
Ma, L. ;
Burke, T. ;
Gu, A. ;
Gascon, P. ;
Roila, F. .
ANNALS OF ONCOLOGY, 2012, 23 (08) :1986-1992
[3]   CINV: still troubling patients after all these years [J].
Aapro, Matti .
SUPPORTIVE CARE IN CANCER, 2018, 26 :S5-S9
[4]   DEFINITIONAL ISSUES IN THE STUDY OF ANTICIPATORY NAUSEA IN CANCER-CHEMOTHERAPY [J].
ANDRYKOWSKI, MA .
JOURNAL OF BEHAVIORAL MEDICINE, 1986, 9 (01) :33-41
[5]  
[Anonymous], AMWF S3 LEITLINIE SU
[6]  
Brafford Megan V, 2014, J Adv Pract Oncol, V5, P24
[7]   Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature [J].
Chow, Ronald ;
Herrstedt, Jorn ;
Aapro, Matti ;
Chiu, Leonard ;
Lam, Henry ;
Prsic, Elizabeth ;
Lock, Michael ;
DeAngelis, Carlo ;
Navari, Rudolph M. .
SUPPORTIVE CARE IN CANCER, 2021, 29 (07) :3439-3459
[8]   2016 updated MASCC/ESMO consensus recommendations: Prevention of acute chemotherapy-induced nausea and vomiting in children [J].
Dupuis, L. Lee ;
Sung, Lillian ;
Molassiotis, Alexander ;
Orsey, Andrea D. ;
Tissing, Wim ;
van de Wetering, Marianne .
SUPPORTIVE CARE IN CANCER, 2017, 25 (01) :323-331
[9]   Antiemetic Guideline Consistency and Incidence of Chemotherapy-Induced Nausea and Vomiting in US Community Oncology Practice: INSPIRE Study [J].
Gilmore, James W. ;
Peacock, Nancy W. ;
Gu, Anna ;
Szabo, Stephen ;
Rammage, Melissa ;
Sharpe, Joyce ;
Haislip, Sally T. ;
Perry, Toni ;
Boozan, Tim L. ;
Meador, Katherine ;
Cao, Xiting ;
Burke, Thomas A. .
JOURNAL OF ONCOLOGY PRACTICE, 2014, 10 (01) :68-+
[10]   A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy [J].
Gralla, R. J. ;
Bosnjak, S. M. ;
Hontsa, A. ;
Balser, C. ;
Rizzi, G. ;
Rossi, G. ;
Borroni, M. E. ;
Jordan, K. .
ANNALS OF ONCOLOGY, 2014, 25 (07) :1333-1339
1234